Study reveals low-dose aspirin reduces liver cancer risk

Image

Study reveals low-dose aspirin reduces liver cancer risk

The findings come from an analysis published in the New England Journal of Medicine and conducted by a team led by investigators at the Karolinska Institutet, in Sweden, and Massachusetts General Hospital (MGH).

Washington D.C. [USA]: Adults who took low-dose aspirin were less likely to develop liver cancer and die from the liver disease-related causes, suggests a recent study. The findings come from an analysis published in the New England Journal of Medicine and conducted by a team led by investigators at the Karolinska Institutet, in Sweden, and Massachusetts General Hospital (MGH).

For the analysis, investigators examined information from Swedish registries on 50,275 adults who had chronic viral hepatitis, a type of liver infection that is caused by the hepatitis B or C virus and is the most common risk factor for liver cancer. Over a median follow-up of nearly 8 years, 4.0 per cent of patients who took low-dose aspirin (less than 163mg/day) and 8.3 per cent of nonusers of aspirin developed liver cancer. Aspirin users had a 31 per cent lower relative risk of developing liver cancer. Importantly, the study showed that the longer a person took low-dose aspirin, the greater the benefit. Compared with short-term use (3 months to 1 year), the risk of liver cancer was 10 per cent lower for 1-3 years of use, 34 per cent lower for 3-5 years of use, and 43 per cent lower for 5 or more years of use.Also, liver-related deaths occurred in 11.0 per cent of aspirin users compared with 17.9 per cent of nonusers over 10 years, for a 27 per cent lower risk.

The benefits were seen regardless of sex, the severity of hepatitis, or type of hepatitis virus (B or C). The risk of internal bleeding--a concern when taking aspirin long-term--was not significantly elevated among aspirin users.

Journal of Oncology Translational Research with ISSN number: 2476-2261 is seeking to publish articles that includes a wide range of topics in this field and creates a platform for the authors to make their contribution towards the journal. The journal covers all aspects of modern research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients and creates a platform for the authors to contribute towards the journal. The authors may forward the manuscript as an email attachment whereby the editorial office takes care of the further processing.

To submit manuscript online please click here: https://www.scholarscentral.org/submissions/oncology translational-research.html
To send as attachment, email to: oncologytransres@oncologyinsights.org

Media contact,
Jessica Rose
Journal of Oncology Translational Research
Email: oncologytransres@medicalresjournals.com
Whatsapp no: +44-1470-490003